Bictegravir Sodium; Emtricitabine; Tenofovir Alafenamide Fumarate Patent Expiration
Bictegravir Sodium; Emtricitabine; Tenofovir Alafenamide Fumarate is Used for treating HIV infection. It was first introduced by Gilead Sciences Inc
Bictegravir Sodium; Emtricitabine; Tenofovir Alafenamide Fumarate Patents
Given below is the list of patents protecting Bictegravir Sodium; Emtricitabine; Tenofovir Alafenamide Fumarate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Biktarvy | US10548846 | Therapeutic compositions for treatment of human immunodeficiency virus | Nov 08, 2036 | Gilead Sciences Inc |
| Biktarvy | US11744802 | Therapeutic compositions for treatment of human immunodeficiency virus | Nov 08, 2036 | Gilead Sciences Inc |
| Biktarvy | US10385067 | Sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepin-8-olate | Jun 19, 2035 | Gilead Sciences Inc |
| Biktarvy | US9708342 | Sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2, 1-b][1, 3]oxazepin-8-olate | Jun 19, 2035 | Gilead Sciences Inc |
| Biktarvy | US9216996 | Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepines and methods for treating viral infections | Dec 19, 2033 | Gilead Sciences Inc |
| Biktarvy | US9732092 | Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]OXAZEPINES and methods for treating viral infections | Dec 19, 2033 | Gilead Sciences Inc |
| Biktarvy |
US8754065 (Pediatric) | Tenofovir alafenamide hemifumarate | Feb 15, 2033 | Gilead Sciences Inc |
| Biktarvy |
US9296769 (Pediatric) | Tenofovir alafenamide hemifumarate | Feb 15, 2033 | Gilead Sciences Inc |
| Biktarvy | US8754065 | Tenofovir alafenamide hemifumarate | Aug 15, 2032 | Gilead Sciences Inc |
| Biktarvy | US9296769 | Tenofovir alafenamide hemifumarate | Aug 15, 2032 | Gilead Sciences Inc |
| Biktarvy |
US7390791 (Pediatric) | Prodrugs of phosphonate nucleotide analogues | Jul 07, 2025 | Gilead Sciences Inc |
| Biktarvy | US7390791 | Prodrugs of phosphonate nucleotide analogues |
Jan 07, 2025
(Expired) | Gilead Sciences Inc |
| Biktarvy | US7803788 | Prodrugs of phosphonate nucoleotide analogues |
Feb 02, 2022
(Expired) | Gilead Sciences Inc |
| Biktarvy | US6703396 | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
Mar 09, 2021
(Expired) | Gilead Sciences Inc |
| Biktarvy | US6642245 | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Nov 04, 2020
(Expired) | Gilead Sciences Inc |
Bictegravir Sodium; Emtricitabine; Tenofovir Alafenamide Fumarate's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List